Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Depreciation & Amortization (CF) of $534670.0 in Q1 2026, up 6.38% quarter-over-quarter from $502587.0 in Q4 2025, and up 31.87% on a YoY basis from $405450.0 in Q1 2025.
Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $534670.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 31.87% year-over-year to $534670.0; the TTM figure through Mar 2026 stood at $2.0 million (up 34.62% YoY), while the FY2025 annual figure was $1.9 million, up 32.54% from the prior year.
- Depreciation & Amortization (CF) was $534670.0 for Q1 2026 at Capricor Therapeutics, up from $502587.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $534670.0 in Q1 2026 to a low of $92490.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $320643.4 across 5 years, with a median of $331406.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 148.78% in 2023, then climbed 22.14% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $191602.0 in 2022, then soared by 60.55% to $307608.0 in 2023, then advanced by 22.14% to $375705.0 in 2024, then surged by 33.77% to $502587.0 in 2025, then gained by 6.38% to $534670.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $534670.0 (Q1 2026), $502587.0 (Q4 2025), and $494726.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | 534,670.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 534,670.00 |
| Mar 31, 2026 | 534,670.00 |
| Dec 31, 2025 | 502,587.00 |
| Dec 31, 2025 | 502,587.00 |
| Sep 30, 2025 | 494,726.00 |
| Sep 30, 2025 | 494,726.00 |
| Jun 30, 2025 | 486,278.00 |
| Jun 30, 2025 | 486,278.00 |
| Mar 31, 2025 | 405,450.00 |
| Mar 31, 2025 | 405,450.00 |
| Dec 31, 2024 | 375,705.00 |
| Dec 31, 2024 | 375,705.00 |
| Sep 30, 2024 | 361,168.00 |
| Sep 30, 2024 | 361,168.00 |
| Jun 30, 2024 | 356,935.00 |
| Jun 30, 2024 | 356,935.00 |
| Mar 31, 2024 | 331,406.00 |
| Mar 31, 2024 | 331,406.00 |
| Dec 31, 2023 | 307,608.00 |
| Dec 31, 2023 | 307,608.00 |